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supporting the family to ensure the best possible outcomes in the face of certain death. Unfortunately, there is
a lack of research evidence on which to base such care
[3-7]. The terminal outcome of the disease may be
known, but the onset, timing, patterns, and severity of
symptoms are not; consequently, best practices and strategies for symptom relief are also unknown. Furthermore,
little is understood about the bio-psychosocial-spiritual
impact on these families and how to support them.
There is a critical need to develop a solid understanding of disease progression and the experiences of these
children and their families over time. We are currently
conducting an innovative 5-year longitudinal study to
identify and track children diagnosed with progressive
metabolic, neurological, or chromosomal conditions and
their families to determine and document the clinical
progression of the condition and the associated bio-psychosocial-spiritual experiences of the family. Our goal is
to close the key knowledge gaps and provide new information about the best care for these vulnerable children
and their families. Our purpose in this paper is to
describe the rationale, development, design, and implementation of this study to assist other researchers who
may be interested in conducting longitudinal research.

Background
Our research team, Transitions in Pediatric Palliative
Care and End of Life, was funded by the Canadian Institutes of Health Research (CIHR) under the New Emerging Team Program (NET) (PET-697#). Led by Dr. Hal
Siden and known as PedPalNet, this team was conceived
to develop a sustainable research program focused on
creating knowledge to optimize provision of care for
children with life-threatening conditions. As far as we
are aware, this is the first interprofessional, multi-centre
team of researchers in pediatric palliative care in the
world. We work together to develop specific research
projects, obtain project operating funds, attract new
research collaborators, and increase research capacity
through trainee support and mentoring.
In an early PedPalNet project, we conducted a Delphi
process to identify high-value areas for Canadian

Page 2 of 12

pediatric palliative care clinicians and researchers.
Through that project, we identified four thematic areas,
three of which have particular relevance to this current
study: (1) identifying what matters most to families; (2)
providing relief of symptoms; and (3) developing evidence to support best practice [8]. A foundational
cohort study to identify family experiences and symptom courses is a logical sequela to the Delphi project.
Dr. Rose Steele, one of the co-principal investigators
for the current study, previously conducted research
with families living with a child who has a neuro-degenerative illness. The resulting grounded theory identified
the basic social process of ‘navigating uncharted territory’ and outlined the trajectory, impact on the family,
factors that modified the experience, and strategies used
by families to manage the experience [9-13]. Lack of
information about what could be expected in the illness
trajectory was identified as seriously hampering a
family’s ability to manage the experience. The current
study, Charting the Territory, builds on the grounded
theory study by focusing on children with a wider range
of progressive metabolic, neurological, or chromosomal
conditions and by using a longitudinal design to
describe the symptom trajectory and further understand
the whole experience for the child, siblings, and parents
from a quantitative perspective.
Life-Threatening Conditions in Children

Two seminal reports from the United Kingdom [14] and
the United States [7] described the broad spectrum of
diagnoses of life-threatening conditions encountered in
children. These conditions are physiologically diverse,
vary in life expectancy and treatments, and more or less
fall into four Quadrants [14] (see Table 1).
Our study focuses on children with Quadrant 3-type
conditions. Quadrant 3-type conditions are those without cure or life-prolonging treatment; good symptom
management and treatment of comorbid illnesses are
emphasized (e.g., aspiration pneumonia) but do not alter
the underlying pathophysiological process. The process
remains inherent in the disease condition. Examples of
diseases that are commonly thought of as fitting into

Table 1 Quadrants of Life-Threatening Conditions in Children[14]
Quadrant 1

Quadrant 2

Life threatening conditions for which curative treatment may be
feasible but can fail.

Conditions where premature death is inevitable, but long periods of
intensive treatment aimed at prolonging life and allowing participation in
normal activities

(e.g., cancer, irreversible organ failures)

(e.g., cystic fibrosis)

Quadrant 3

Quadrant 4

Progressive conditions without curative treatment options, where
treatment is exclusively palliative and may extend over many years.

Irreversible but non progressive conditions with severe disability susceptible
to health complications and premature death.

(e.g., neurodegenerative, metabolic disease)

(e.g., anoxic brain injury, severe cerebral palsy)
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this category include: leukodystrophies, spinocerebellar
degenerative diseases, and some chromosomal anomalies, including aneuploid states. Even though the specific
diagnoses that tend to fall into Quadrant 3 are varied
and numerous, clinically they are similar in functional
impairments and diversity of symptoms that limit quality and duration of life.
The number of children with rare, progressive diseases
that fall into Quadrant 3 is large relative to the other
Quadrants and these children require significant health
care attention, yet surprisingly little has been comprehensively explored and documented about the illness
trajectory of these conditions. The onset of the disease
and symptoms and the length of survival time for these
children are virtually unexplored. We chose to conduct
research with this group for several reasons:
• These children and their families are major users
of health care services for acute, chronic, and endof-life care [2].
• There is a major impact on families caring for
these children [15].
• These children account for about 50% of children
receiving palliative care [16-22].
• As a group, Quadrant 3-type conditions are a significant cause of death in childhood [1,19,23,24].
• There is a lack of research in this group compared
with other areas, such as cancer [25].

Knowledge Gaps

Both positive and negative outcomes of the experience
have been documented for parents and siblings of these
children [9-11,13,26-32] but there is a paucity of
research addressing the overall experience of the child
and family. It is unclear if outcomes are isolated to specific times, if they are present throughout the experience, or if/how they may change over time. A holistic
approach that concurrently examines bio-psychosocialspiritual dimensions for family members would allow for
a more complete picture of the experience.
Given the prevalence of Quadrant 3-type conditions
and the associated physical, psychological, and financial
costs, it became clear that a longitudinal, prospective
study that follows the child and family for as long as
possible as they move from diagnosis through death and
into bereavement was imperative to document the natural course of the child’s condition and the experience
of the family. This study was conceived as a way to
address this important research area. Results of this
study will inform families and clinicians about what they
might anticipate during the child’s trajectory towards
death.
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Methods/Design
Study Objectives

Our study is a prospective longitudinal study with three
objectives:
a) Establish a cohort of children with non-curable,
life-threatening conditions.
b) Determine and document the natural history of
the symptom progression of these conditions.
c) Determine and document the bio-psychosocialspiritual trajectory of parents and siblings.
Specific research questions include:
1. What is the clinical illness trajectory, and its
impact, for children with non-curable, life-threatening conditions, specifically: pain, breathing or
respiratory problems, feeding difficulties, alertness
and interaction changes, sleep problems, seizures,
constipation, and functional abilities?
2. What is the bio-psychosocial-spiritual trajectory,
and its impact, for families when a child has a noncurable, life-threatening condition, specifically outcome variables of: family functioning; marital satisfaction; parent health, anxiety, depression, stress,
burden, spirituality, grief, and growth; and sibling
health and coping?
3. Do these child and family outcome variables
change over time?
4. What relationships exist among the child and
family outcome variables and do these relationships
change over time?

Study Design

In this longitudinal research study, we are using quantitative methods with established instruments and chart
reviews. Data collection is taking place along two parallel streams: one examining the child’s clinical symptoms,
and the other examining bio-psychosocial-spiritual
aspects of the experience for family members. Under the
current funding, children and their families will be followed for a minimum of 18 months, based on when
they enter the study. However, we hope to obtain
further funding beyond this initial 5-year study and
extend this cohort for a longer duration. We also hope
to expand data collection in the future to include qualitative interviews that capture other aspects of the
experience. We are recruiting children and families with
new diagnoses in order to maximize understanding of
the condition trajectory, but we also are including those
with established diagnoses as some symptoms may only
arise later in the condition course. This approach should
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provide an opportunity to better understand symptoms
and parent/sibling experiences at different times along
the trajectory. Some children may die during the study
period, but the intent is to follow those families through
the course of the illness and into bereavement. This
descriptive, correlational design will allow for efficient
and effective collection of large amounts of data within
a naturalistic setting and for investigation of complex
relationships that may exist among the clinical and biopsycho-social variables.
Eligibility Criteria

Only children with Quadrant 3-type conditions that fall
into the group of progressive metabolic, neurological, or
chromosomal conditions are eligible for the study. Children who have been provided with potentially curative
therapies, such as stem cell transplantation for metabolic
conditions, are excluded. The inclusion list was developed from a literature review, palliative care program
data (Canuck Place Children’s Hospice, Vancouver), and
an iterative review process involving pediatric palliative
care physicians and specialists in the fields of Neurology,
Genetics, and Metabolic Diseases. The resultant list is in
accordance with current approaches to pediatric palliative care [14] and work on mortality in childhood Complex Chronic Conditions [23,33].
Determining who is eligible for recruitment from a
theoretical “Quadrant” of conditions initially proved
challenging. The Quadrant model, first described as
“Categories” by the British charity ACT, is primarily
useful as a conceptual framework for understanding the
broad variety of children and families receiving pediatric
palliative care. Clinically, the model maps broadly onto
an identifiable population of eligible children. Before
recruitment started, the clinicians began to generate a
list of sample eligible diseases in order to establish who
would be specifically eligible. From the original list, a
system of categories was further developed by geneticists, neurologists, and biochemical disease specialists in
our study sites. This list included a category for those
conditions that could be treated with curative therapies,
but where the child would be eligible if the treatment
was failing, and those conditions where the trajectory
may not always display the progressive component that
is classic for Quadrant 3. The list quickly became iterative in that the clinicians and researchers continue to
make notes and compare their new diagnoses to the original list, adding and noting where there is disagreement. This purposive sampling of diagnoses allows the
inclusion of children whose disease is progressive, and
the constant iterations permit a theoretical model
to translate into a practical, useful clinical document to
determine eligibility. Potential participants are compared
to the list and to an Eligibility Criteria Checklist to
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determine whether or not to approach the family (see
Figure 1).
Families may have various ways of determining who is
a member of their family, but for the purposes of this
study, “family” includes only the biological, adoptive,
step-parents, or legal guardian and biological, adoptive,
or step-siblings with whom the affected child lives most
of the time. Children in foster care are not eligible
because some foster parents only provide short-term
care, the foster setting may change during the course of
the study, or there may be legal issues with obtaining
consent. Families who have multiple children affected
with these conditions are eligible, but only those affected
children 0-19 years of age are included in the study. A
parent may provide data about more than one eligible,
affected child. A minimum of one parent must agree to
participate on his/her own behalf, plus provide the
required information on the ill child throughout the
study. In addition, all siblings age 7-18 years are invited
to participate. The age ranges were chosen because the
instruments we are using have been validated for children of those ages. Participants must speak and write
English or French as data collection is only available in
the two official Canadian languages.
Study Recruitment

Three hundred children and their families are being
recruited in six cities across Canada (Vancouver, Calgary, Edmonton, Toronto, Ottawa, and Montreal). Sites
were chosen to maximize access to the population based
on (a) the numbers of children diagnosed annually, (b)
the presence of a palliative care team member as an
onsite collaborator for recruitment and ethics, and (c)
the availability of a specialist clinician/team in Metabolic
Diseases, and/or Genetics, and/or Neurology clinics who
follow these children and can support access to subjects
and clinic records. Prior to commencing recruitment at
a participating site, institutional ethics approval was
obtained from the Research Ethics Board (REB) of the
hospital, as well as from each of the universities where
the participating co-investigators held their primary academic positions.
The protocol and all study materials underwent minor
modifications to accommodate different requirements at
each site. These differences primarily reflect the varying
approaches of Research Ethics Boards regarding recruitment. Each REB approved a different method of initial
contact between the researchers and the study participants. In provinces where Health Information Protection
legislation is strictest, the Research Assistant (RA) is
prohibited from contacting families without written
approval from at least one of the parents. At other sites,
contact information is accessible to the RA who may
call or visit with a family in clinic after an introduction
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Figure 1 Eligibility Criteria Checklist
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from the clinician or clinic nurse. All sites approved the
more passive “call back” method, where clinicians mail
out invitations from the clinic to the family. Families
who are interested call a toll-free 1-800 number for
more information. The site RA provides any follow-up
information for interested families. None of the sites
allow the researchers to recruit the families directly,
especially in situations where the Site Investigator also
tends to be the child’s clinician. This non-coercive procedure is intended to prevent undue pressure on the
family to participate.
When the initial recruitment met with challenges,
especially where the RA requires a lengthy introduction
process or is unable to identify eligible children due to
privacy protection laws, two alternate recruitment methods were added to the protocol. In order to maximize
the scope of our enrollment, an online recruitment
method was proposed. The REB approved clinicians
giving out information about our study website. Secondly, disease-specific organizations such as the MPS
Society, and other organizations such as the Rare Diseases Foundation and the Canadian Organization for
Rare Disorders (CORD), are able to aid in recruitment
of eligible families by distributing information about the
study on their website and in organizational newsletters.
Each organization also has a list of parent support networks to which appeals can be made for assistance with
study recruitment.
Accrual and Attrition

The sample size of 300 is pragmatically motivated as we
anticipate that 50 participant families can be recruited
in each of the 6 sites. We are confident this sample size
is ample for descriptive purposes, e.g., it will enable us
to estimate simple proportions with a standard error not
exceeding.03. Across the collaborating sites, approximately 300 children are diagnosed annually with the
eligible rare, progressive conditions and another 750 children are followed in the clinics. Therefore, about 1650
families would be eligible or become eligible over the 36
month accrual period. Based on previous work investigating recruitment and retention in a longitudinal palliative care study, typically 80-90% of individuals are
expected to be receptive to research [34], so a sample
size of 300 is feasible. As with any longitudinal study,
attrition will likely occur over time, but parents in
pediatric palliative care often participate in research as a
way of helping others, even when they find it challenging practically (e.g., time) or emotionally (e.g., reliving
memories) [11].
We anticipate minimizing attrition through employing
a number of strategies highlighted in the literature
[35-38]. RAs develop a solid relationship with families
through an initial face-to-face visit, telephone contact at
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prescribed intervals, and letters to thank families for
their participation. Continuity of RAs is expected to
contribute to the trusting relationship that is needed to
help participants feel more connected to and interested
in the study over time. Efforts are made to respect
families’ time and recognize the value of their contribution. RAs schedule data collection at the family’s convenience and regularly express verbal and written
appreciation for their participation in the study. In addition, along with the blank questionnaire package at each
6-month data collection point, including at baseline, and
regardless of how many family members participate,
families are given a cheque for $40 as a token of appreciation. We expect that some parents may use the
money to help pay for respite while they complete the
questionnaires, but there are no restrictions on how parents can spend the token of appreciation.
Data Collection

Data collection is taking place along two parallel timelines: one recording the child’s clinical symptoms
monthly and the other examining bio-psychosocial-spiritual aspects of the experience for family members every
6 months. Instruments being used in the study are
detailed in Table 2 with information about who completes each instrument and how frequently it is completed. Data are also collected through chart reviews on
entry into the study and at the end of the study or at
the time of the child’s death. Data collection will continue for a minimum of 18 months, depending on how
early a family enrols in the study, providing a minimum
of 4 data collection points. The method and frequency
of data collection were chosen based on longitudinal
studies with seriously ill adults that indicate trends/
changes should be detectable with this timeline, while
minimizing burden as much as possible on individuals
who already have significant burdens placed upon them
due to the nature of their caregiving experience [37,39].
The questionnaire package and the timing of data collection were previously reviewed and discussed with parents of children with a life-threatening condition who
had at least one child enrolled on a hospice program.
These parents agreed the study was feasible and the
burden on families would not be too great.
We prefer that baseline data, including written
informed consent in accordance with institutional ethics
guidelines, are collected in person in order to establish a
relationship between the RA and the family from the
beginning of the study. However, occasionally a family
may be unable to participate in a face-to-face meeting
and so we have developed a telephone process for
explaining the study and arranging for families to submit written consent and completed questionnaires without actually meeting with the RA. Questionnaire
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Table 2 Instruments, Participant Who Completes, and Timing of Data Collection
Instrument

Who Completes

Timing

Demographic
Information

Demographic Sheet

Completed by parent

Baseline and updated every 6 months

Family Level
Data

Family Adaptability and
Cohesion Evaluation Scale
(FACES III)[61]

Completed separately by each parent who agrees to
participate in study

Baseline and every 6 months

Couple Level
Data

Norton Quality of Marriage
Index[62]

Completed separately by each parent who agrees to
participate in study, when currently in spousal/
common law relationship

Baseline and every 6 months

Individual Level • SF 12[63]
Data: Parent
• State Trait Anxiety
Inventory[64]
• Center for Epidemiologic
Studies Depression Scale
(CES D)[65]
• Perceived Stress Scale[66]
• Burden Scale[67]
• Post Traumatic Growth
Inventory (PTGI)[68]
• Spiritual Involvement and
Beliefs Scales (SIBS)[69]
• Grief Scale
• Impact of Participation

Completed separately by each parent who agrees to
participate in study

All at baseline and every 6 months,
except for Impact of Participation (after 1
year and at end of study)

Individual Level • Clinical Symptoms
Data: Affected
Child

• Completed by parent

• Baseline and once a month

• Completed by RA through observation or parent
report

• Baseline and annually

• Younger version completed by siblings age 7 to 12
years; older version for 13 to 18 years

All at baseline and every 6 months

• Pediatric Evaluation of
Disability Inventory (PEDI©)
[45 47]
Individual Level • Kidcope[70]
Data: Sibling
• Child Behavior Checklist
(CBCL)[71]

• Completed by parent for siblings age 7 to18 years

• Youth Self Report (YSR)[72] • Completed by siblings age 11 to18 years and able to
complete by self

packages are mailed to these families for initial and subsequent data collection. For the newly diagnosed family,
baseline data ideally is obtained before changes occur,
so within 4-6 weeks of diagnosis, but families where the
child has an established diagnosis may be recruited at
any stage in the disease process. Assent/consent (the
distinction being based on age) is obtained from all
child participants who are cognitively able to assent/
consent for themselves.
No further consent forms will be signed during the
study. Completed questionnaires signify ongoing consent. At each data collection point, families are
reminded in the preamble to the questionnaire of their
right to refuse participation at any time or to not answer
certain questions. To ensure privacy and confidentiality
for returns from multiple members of a family, separate
envelopes are included for each participating subject to
seal their questionnaires before placing them in the
larger pre-paid, self-addressed return envelope.
Clinical symptoms stream

Data about the ill child’s clinical symptoms are collected
monthly using an online instrument designed by the

research team in consultation with other experienced
Canadian clinicians, families, and a psychometrician.
The instrument is a modification of the PediQUEST
symptom recording tool and the revised Memorial
Symptom Assessment Scale (7-12), developed for symptoms in children with cancer [40-43]. Symptoms are
being tracked for timing of onset (symptom latency)
[44], frequency, and distress. Assessed symptoms include
difficulties with breathing or respiration, feeding issues,
pain, alertness and interaction, sleep issues, seizures,
and constipation. Parents of children who received
palliative care services from the Canuck Place Children’s
Hospice reviewed the instrument and affirmed that it
includes the most common and/or troublesome symptoms. The instrument takes 6 to 10 minutes to complete
and parents may choose either an online or telephone
method of completion. If the parent chooses the online
method, s/he receives an email every month with a
reminder to visit the secure website and complete a web
survey. If the parent chooses the telephone method, the
RA calls at monthly intervals to administer the instrument and enter the scores manually into the online
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system while the parent reports on the child’s symptoms. Parents were given the choice of administration
method for the symptoms’ instrument to allow flexibility
and accommodate any families lacking Internet access.
With assistance from the RA, the parent assesses the
ill child for cognitive and motor ability on enrolment
into the study and annually using the Pediatric Evaluation of Disability Inventory (PEDI) [45-47]. In addition
to measuring functional abilities, the PEDI evaluates the
amount of Caregiver Assistance and Modifications
required in caring for the child. Data are collected using
this instrument from the time the family enrolls in the
study until the time of the child’s death or the end of
the data collection period, whichever comes first. RAs
complete the Caregiver Assistance and Modifications
section with the designated parent. To minimize potential error, all RAs involved with this study were trained
to complete the PEDI by an occupational therapist.
Further, to assess whether there is consistency across
the RAs’ ratings, inter-rater reliability testing was completed. Analysis of the reliability involved calculating the
Intra-class Correlation Coefficients (ICC) for the RA
scores on a sample case from the manual. Excellent correlation among the RAs was found for Caregiver Assistance, with an ICC value of 0.959 overall (Self-Care:
0.865; Mobility: 0.976; Social Function: 0.760). Testing
on the Modifications scale showed an ICC value of
0.651 overall (Self-Care: 0.550; Mobility: 0.674; Social
Function: 0.400). Reliability was high for the Caregiver
Assistance scale, and moderate-to-low for the Modification scale. RAs received feedback about ways to improve
their administration of the tool in order to maintain
ongoing reliability.
Health records are reviewed by the RA at baseline to
document the circumstances surrounding the diagnosis
and the period leading up to the diagnosis, as well as
the prevalence and incidence of symptoms recorded
since diagnosis. If the child dies during the course of
the study, a chart review is conducted to document
details of the care provided just prior to the death and
the circumstances of the death. Chart reviews also will
be conducted for living children living at the conclusion
of the study.

widely used in previous research with similar populations. The exception is the instrument used to measure
grief, which was designed by the research team in consultation with other experienced Canadian researchers.
The instrument is a modification of the Inventory of
Social Support (ISS), a 5-item self-report questionnaire
about what helps or makes it harder to cope with grief
[48]. The questionnaire package can be completed in
about one hour, as estimated by parents who pilottested the instruments.
Unlike the clinical symptom stream where data are
collected online or by telephone, the bio-psychosocialspiritual instruments are completed at home and mailed
to the main site. This method of data collection allows
family members to complete questionnaires in their own
home, at their own pace, rather than having to commit
to a potentially lengthy interview time. At baseline, the
RA obtains permission to meet with the family during a
routine clinic visit or at another more convenient location such as the family home, whichever is more amenable to the family. Once the baseline visit is complete,
no further face-to-face meetings with the family are
required. If the timing is appropriate and participants
want to complete subsequent questionnaires face-to-face
with the RA, then they may do so at the clinic visit.
Some of the children will likely die during the course
of the study; indeed, we already have faced this outcome
with one family. Clinicians involved with the child and
family notify the site RA when a child dies. The RA
immediately mails a hand-written card of condolence to
the family. The RA also conducts a chart review to
document the circumstances of the death. Other data
collection is suspended for the family until 6 months
after the child’s death. After that time, the RA contacts
the family by telephone to express condolences to the
family and obtain verbal agreement for continued participation in the study. Data collection in the bio-psychosocial-spiritual stream then continues at 6 month
intervals until the end of the study. Demographics are
updated at 6 month intervals throughout the study and
into the bereavement period.

Bio-psychosocial-spiritual stream

Regardless of data collection method (in-person, on-line,
telephone, or mail) all data from the multiple sites are
entered into Daciforms, a single web-based database
(Dacima Software, Inc., Montreal, QC). Daciforms
allows researchers at multiple locations to enter and
review data online. Each study staff member is assigned
a unique password and Site ID that allows secure access
to the centralized data. From Daciforms, data are
exported into SPSS (IBM, Chicago) for descriptive analysis. Once we have sufficient data points, advanced data
analysis and modeling will be performed using the

Data about the bio-psychosocial-spiritual experiences of
family members are collected at 6 month intervals, from
the time the family enrolls in the study until 6 months
prior to the end of the study (to allow for final analyses
and write-up), even if the child dies beforehand. The
outcomes being measured in the study include: family
functioning; marital satisfaction; parent health, anxiety,
depression, stress, burden, spirituality, grief, and growth;
and sibling health and coping. Most of the measures
have demonstrated reliability and validity and have been

Analysis Plan
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open-source R statistical package (GNU General Public
License). Analysis for the clinical symptoms stream
involves describing the frequency and severity of symptoms based on the clinical symptom instrument. Following the examination of simple descriptive tables, we will
fit longitudinal ordinal regression models including variables representing condition type (neurological, metabolic, or chromosomal), time from diagnosis, age, and
sex. We will apply both hierarchical random effect [49]
and GEE (generalized estimating equation) [50] models.
Akaike’s Information Criterion (AIC) [51] will be used
to select terms (including interactions) in random-effect
models; resulting models will be re-fit using GEE to provide population-level estimates.
The symptom instrument includes items on change
relative to previous questionnaire administration based
on the expectation that ceiling effects will be modulated
by symptom progression. To capture this phenomenon,
we are defining a “symptom breakthrough” as occurring
if a symptom’s severity is at ceiling at time t but
reported to have worsened at time t+1. We will apply
longitudinal logistic regression models following the
general strategy outlined previously to describe patterns
of incidence.
Bio-psychosocial-spiritual measures will be analyzed in
a similar manner with descriptive statistics and longitudinal regression models, and we will incorporate random effects to allow for correlation within respondents
over time and between respondents within families.
Relationships between symptom progression and biopsychosocial-spiritual measures will be investigated in
an exploratory fashion. Due to the complex nature of
the data analysis, it was important to involve a statistician (RB) from the outset.

Ethical Issues
As part of designing the study, and in order to preemptively address potential ethical concerns, we consulted
with parents of children who received pediatric palliative
care at Canuck Place Children’s Hospice in Vancouver.
These parents provided advice on timelines and frequency of data collection. Parents highlighted two
issues: (1) the crucial need for this type of research and
(2) the potential need for emotional support to families.
RAs are sensitive to this potential need and have been
trained in how to communicate with families and to
ascertain whether support is needed. In addition, a
detailed list of institutional and community resources to
support families is available for each site and is given to
families on admission to the study. Families also are
reminded at each data collection point and in a semiannual newsletter that the list of resources is available.
The lists of local resources are updated semi-annually
and posted on the study website.

Page 9 of 12

Limitations
One limitation that arose early on was the challenge of
defining a theoretical group of children with Quadrant 3
conditions using a rigorous “Inclusion/Exclusion
Criteria” checklist. Initially, clinicians were unsure what
Quadrant to categorize a diagnosis under and which children could participate. However, the evolving Eligible
Disease List that was built from the ground up has
involved the clinicians in determining eligibility and has
encouraged their participation in refining the eventual
criteria. Rather than dictate the eligibility, the list has
been strengthened by ongoing discussion and iterative
review. While the current study focuses on families of
children with Quadrant 3-type life-threatening conditions, it is anticipated that the method may be applied to
other groups of diseases. A similar process could be used
to identify eligibility in other studies. Researchers in
future studies could identify similarities and differences
amongst the Quadrants and build a comprehensive picture of important strategies within pediatric palliative
care to ensure optimal care for all affected families.
Another potential limitation inherent in the current
study design results from using multiple modalities of
data collection. We chose to use multiple modalities of
data collection (online, phone, written, and in-person)
throughout the study in order to provide the most flexibility for participating families. There is some concern
in the literature that people respond differently to questions, particularly sensitive ones, based on the method
used to answer questions [52]. However, we believe that
it is most important for families to have some choice in
how they take part in the study and to choose what will
fit best with their schedule, lifestyle, and familiarity with
technology. This flexibility is important in minimizing
family burden related to the study and attrition of
families from the research. Our final data analysis will
reveal any differences in mode of data collection and its
possible impact on the research findings.
Lastly, instruments used in the study design are
entirely quantitative. The published instruments demonstrate strong reliability and validity, therefore they were
the first choice for initial measurement of this uncharted
population. However we recognize the need for and
importance of also collecting qualitative data from
families. We have already had strong feedback from parents about how important it is to “sit and talk” with the
families in order to better understand their full experience. Our hope is to obtain future funding, so that we
can expand on quantitative findings of our study
through interviews.
Discussion
Charting the Territory is a distinctive study because of
the focus on childhood conditions without cure or
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life-prolonging treatment; use of a prospective, longitudinal design; and simultaneous attention to the affected
child, siblings, and parents. There is some reluctance to
conduct research with this population because of the
perceived negative impact on vulnerable families, however there is mounting evidence to suggest that participation in research during the illness experience and
after a child’s death is a positive experience for participants and should be conducted. Some studies have highlighted parents’ eagerness to share the story of their
child’s illness and death and to provide input to help
other families [53-55]. While parents report that discussions of their child’s diagnosis and/or death are at times
difficult, the vast majority of parents deny any negative
impact or distress caused by participating in research
[56-60]. However, very few studies have included a systematic evaluation of the impact of participating in this
type of research, and none of the published studies evaluated a longitudinal study design.
To add to the small body of existing research and to
guide the study team in development of future longitudinal studies with similar populations, we have incorporated a component to evaluate the impact on parents of
participating in the study. This evaluation will be completed by all participating parents through a written survey after one year of enrolment in the study and at the
end of the study. As well, at the end of the study the
RA will contact the designated parent by telephone to
debrief the experience and formally end the relationship
with the family. Any suggestions for how the process or
procedures of the study could be improved upon will be
sought formally at that time, but families also are
encouraged to provide feedback throughout the study. If
any other family members wish to speak directly with
the RA at the end of the study to provide feedback or
say goodbye, this conversation will be arranged. A final
personalized thank-you and good-bye letter will be sent
by the RA on behalf of the research team to the family
after this closure call.
We expect that this research will advance knowledge in
the fields of family caregiving, subspecialty pediatrics,
pediatric palliative care, and bereavement by providing
some of the first-ever detailed descriptions of the clinical
symptom trajectory and bio-psychosocial-spiritual aspects
for these conditions. We will close gaps in knowledge and
contribute to the limited, existing body of knowledge specific to Quadrant 3-type conditions in the emerging area
of pediatric palliative care. Extending existing research
will enable policy makers and practitioners to better
understand the realities of families where a child has a
progressive, life-threatening condition. Baseline information about critical periods for symptom management and
psychosocial support will enable the design of appropriate
intervention and support strategies.
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Specifically, the study will provide information to
families about what they might expect as the child’s illness progresses; assist with the development of symptom
assessment and evaluation tools, especially in non-verbal
children; provide critical information to pediatricians,
metabolic, genetics, and neurology specialists, family and
child health professionals, and pediatric palliative care
clinicians that will assist them to better support children
and families; provide a cohort and data to support interventional research in symptom management and care of
families; and lay the groundwork for future studies. As
noted by the parents, this study will help them learn
about expected trajectories; they will then use this
knowledge in decision-making and in advocating.
Currently, without this knowledge parents and health
professionals continue to ‘navigate uncharted territory.’
In this study the map needed to anticipate outcomes
and to guide informed decision-making throughout their
journey will be developed.
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